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Cholinergic hypofunction is associated with decreased attention and cognitive deficits in
the central nervous system in addition to compromised motor function. Consequently,
stimulation of cholinergic neurotransmission is a rational therapeutic approach for
the potential treatment of a variety of neurological conditions. High affinity choline
uptake (HACU) into acetylcholine (ACh)-synthesizing neurons is critically mediated by
the sodium- and pH-dependent high-affinity choline transporter (CHT, encoded by
the SLC5A7 gene). This transporter is comparatively well-characterized but otherwise
unexplored as a potential drug target. We therefore sought to identify small molecules
that would enable testing of the hypothesis that positive modulation of CHT mediated
transport would enhance activity-dependent cholinergic signaling. We utilized existing
and novel screening techniques for their ability to reveal both positive and negative
modulation of CHT using literature tools. A screening campaign was initiated with a
bespoke compound library comprising both the Pfizer Chemogenomic Library (CGL) of
2,753 molecules designed specifically to help enable the elucidation of new mechanisms
in phenotypic screens and 887 compounds from a virtual screening campaign to
select molecules with field-based similarities to reported negative and positive allosteric
modulators. We identified a number of previously unknown active and structurally distinct
molecules that could be used as tools to further explore CHT biology or as a starting point
for further medicinal chemistry.
Keywords: HACU (high affinity choline uptake), acetylcholine, solute carrier, SSM electrophysiology, phenotypic
screening, mass spectrometry, small molecule screening, SLC5A7
INTRODUCTION
Cholinergic neurons are responsible for transmitting signals to a wide range of tissues within
the peripheral and central nervous systems. As a result, they are involved in a variety of crucial
biological processes including muscle contraction, cognition, learning, memory, and control
of autonomic functions (Woolf and Butcher, 2011). Decreased acetylcholine (ACh) levels or
expression and/or function of the neurotransmitter receptors, in selected areas of the nervous
system, have been described in several neurodegenerative diseases such as Alzheimer’s, Parkinson’s
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and Huntington’s as well as in psychiatric disorders such as
schizophrenia. The high affinity choline transporter (CHT)
is responsible for uptake of choline into cholinergic nerve
terminals, where it is acetylated by choline acetyltransferase
(ChAT) to form the neurotransmitter acetylcholine. The
transporter protein was cloned and identified by Okuda and co-
workers in 2000, and shown to exhibit high-affinity, sodium-
dependent choline uptake (Km∼2 µM) which could be inhibited
by hemicholinium-3 (HC-3) with a Ki of 1–5 nM (Okuda
and Haga, 2000; Okuda et al., 2000; Apparsundaram et al.,
2001). Collective evidence indicates that CHT density in the
synaptic plasma membrane is the primary variable determining
the capacity of cholinergic neurotransmission (Ferguson and
Blakely, 2004; Ribeiro et al., 2006; Black and Rylett, 2012).
The majority of CHT is localized intracellularly including
a proportion present on ACh-containing synaptic vesicles,
suggesting an elegant mechanism for linking ACh release to
CHT membrane density and choline re-uptake (Ferguson et al.,
2003; Apparsundaram et al., 2005): vesicular fusion is able to
support a rapid biosynthetic response to neuronal stimulation.
Manipulations that increase the rate of choline uptake, Vmax,
also increase transporter density in the synaptic membrane. Post-
translational modifications (PTM) such as phosphorylation and
ubiquitination have been shown to modulate activity state in
addition to subcellular trafficking via endosomal compartments
into synaptic vesicles (Cooke and Rylett, 1997; Kar et al., 1998;
Gates et al., 2004; Misawa et al., 2008; Black et al., 2010; Yamada
et al., 2012; Hartnett et al., 2014; Parikh et al., 2014). Additional
regulation likely includes specific protein-protein interactions;
however the complex partners are not well-defined (Kar et al.,
1998; Ribeiro et al., 2003; Parikh et al., 2006, 2014; Brock et al.,
2007;Misawa et al., 2008; Pinthong et al., 2008; Cuddy et al., 2012,
2014, 2015; Kristofikova et al., 2013; Fishwick and Rylett, 2015).
This raises the possibility of modulating CHT surface localization
to impact on transport Vmax in addition to direct modulation of
transport function through affinity (Km) or rate.
Presynaptic mechanisms influencing ACh synthesis and
release have received little attention as therapeutic strategies for
modulating cholinergic function, despite good understanding
and high conservation of cellular mechanisms. Indeed, ACh
release cannot be sustained without presynaptic transporter
mediated recapture of choline, as demonstrated by genetic and
pharmacological studies (Ferguson et al., 2004; Ferguson and
Blakely, 2004; reviewed in Brandon et al., 2004; Apparsundaram
et al., 2005; Parikh and Sarter, 2006; Bazalakova et al., 2007;
Parikh et al., 2013). Neurons enhance CHT activity in response
to neuronal activity to enhance ACh production. Thereby, if
this mechanism were to be modulated by compounds, this
offers a potentially impactful approach to augment cholinergic
signaling for therapeutic purposes. Furthermore, the mechanism
focuses on clearance of choline from the synapse rather
than ectopic stimulation of acetylcholine receptors through
acetylcholinesterase inhibitor (AChEI) treatment.
We therefore sought to leverage the comparatively high
level of characterization and potential interest of CHT as
a target to develop a platform to assess existing and novel
approaches to characterizing electrogenic transporter function
in a drug discovery context. We prioritized approaches focused
on direct assessment of transporter function as an output
that could be developed further into primary medium- and
high-throughput screens. We also assessed potential secondary
screening modalities using alternative assay formats such as
assessment of transporter localization. We performed a focused
screening campaign using a bespoke compound set. There is
comparative paucity of relevant known tool molecules that
modulate CHT function: published orthosteric inhibitors include
hemicholinium-3 (HC-3) and related analogs which have been
broadly used since their first discovery in 1955 (Ferguson and
Blakely, 2004). In addition there is the recently described negative
allosteric modulator (NAM) ML-352 (Ennis et al., 2015) and
putative positive modulators of transporter function including
MKC-231/coluracetam (Bessho et al., 2008; Takashina et al.,
2008a,b) and staurosporine (STS) (Ruggiero et al., 2012). ML-352
andMKC-231 were used as seeds for generating the first set of 887
compounds via Cresset software (a computational approach that
generates a 3-dimensional electrostatic shape or “field” which
illustrates how the compound may interact with the target).
The second set comprised the Pfizer Chemogenomic Library
(CGL) of 2,753 compounds specifically designed to support target
identification from phenotypic screening (Jones and Bunnage,
2017). We identified a number of active, previously unknown
CHT positive allosteric modulator (PAM) chemotypes that could
be used either as tools or as starting points for further medicinal
chemistry activities.
MATERIALS AND METHODS
Cell Line Generation and Culture
Sequences corresponding to full-length CHT (NM_021815.4)
and LV-AA mutation at residues 531–532 (Ribeiro et al., 2005;
Ruggiero et al., 2012) were codon-optimized for expression
in human cell lines and custom-synthesized by GeneArt
(LifeTech). Constructs were designed with a N-terminal FLAG
epitope (Cuddy et al., 2012) and cloned into the pLenti6.3/V5
DEST vector which also contained a C-terminal V5 epitope
tag (LifeTech). Lentiviral particles were generated (ViraPower,
Thermofisher Scientific) and used to transduce HEK-293 cells
(Sigma Aldrich). Pools of stable transformants were selected
with 8 µg/mL Blasticidin. In addition, SH-SY5Y cells (ATCC)
were transduced with a CHT construct tagged with GFP at
the C-terminal (Origene, PS100071) or a FAP tag at the N-
terminus (Sharp Edge Laboratory). Both stable pools and single
clones were expanded. HEK-293 cells were cultured in DMEM
High glucose (Gibco # 21969-035) supplemented with 10% FBS
and 4 mM Glutamine (Thermofisher Scientific). SH-SY5Y cells
were cultured in DMEM:F12 with Glutamine (Gibco # 11320-
033) supplemented with 15% FBS and 1x NEAA (Thermofisher
Scientific).
Field-Based Approach to Identifying Novel
CHT Modulators
The Cresset field based virtual screening tool, Blaze (formerly
called FieldScreen), (Cheeseright et al., 2008, 2009) was utilized
to search the full Pfizer compound screening collection to
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identify compounds similar to literature CHT positive allosteric
modulator (PAM) MKC-351/coluracetam (Takashina et al.,
2008a,b) or CHT negative allosteric modulator (NAM) ML-
352 (Ennis et al., 2015). Similarity was assessed using 50%
3D electrostatic and hydrophobic properties (Cheeseright et al.,
2006) and 50% shape (Grant et al., 1996). This field was then
used as a template to virtually screen the Pfizer file for additional
compounds with a similar field and potentially related biological
activity. For each virtual screening run, the top 500 compounds
from the Pfizer compound collection, based on Blaze score, were
selected. The set of 1,000 compounds identified from the PAM
and NAM virtual screening campaigns was further filtered based
on compound availability and removal of chemically unattractive
groups (Stepan et al., 2011) to generate a test-set set of 887
compounds.
Chemogenomic Compound Library
The Pfizer Chemogenomic Library (CGL) contains 2,753
selective small molecules covering 1,043 distinct biological
targets (Jones and Bunnage, 2017). The CGL was created to
support phenotypic screening with the purpose of expediting
target identification. A hit from the set suggests the annotated
activities of that pharmacological agent may be involved
in perturbing the observable phenotype. Multi-parameter
optimization was used in the creation of the library to
ensure appropriateness of molecules for cell-based screening
(including assessments of permeability, solubility, cytotoxicity
and selectivity). CGL compounds were selected on their potency
against their primary annotated target at a concentration equal to
or less than 500 nM where possible.
SURFE2R
Preparation of CHT Containing Membrane Fragments
A single cell clone of HEK293 overexpressing CHT (CHT-
WT4) cells was used to generate membrane fragments to
assess on the SURFE2R platform. Cells were grown to 80%
confluence and harvested. The membrane fraction was collected
by ultracentrifugation and the plasma membranes were isolated
by density gradient centrifugation (Schulz et al., 2008).
Thiol-Coating of the Sensors
All experiments were performed on the SURFE2R N1 device and
the matching N1 sensor blanks (Nanion Technologies GmbH,
Munich). The sensor blanks include a 3 mm diameter gold
surface inside a small well coated by incubating 50 µL of 0.5 mM
1-octadecanethiol dissolved in isopropanol for 30 min, rinsed
once with isopropanol and twice with water (ddH2O) and dried
for 30 min at room temperature.
Preparation of the Solid Supported Membrane (SSM)
Buffers were prepared according to the following schedules:
Potassium buffer–30 mM HEPES, 5 mM MgCl2, 140 mM KCl,
pH 7.4 with KOH; Sodium buffer—30mMHEPES, 5mMMgCl2,
140 mM NaCl, pH 7.4 with NaOH; Choline buffer—Sodium
buffer + 100 µM Choline Chloride. 7.5 µg/µL DPhPC (Avanti
Polar Lipids) was dissolved in n-Decane. 1.5 µL were added onto
the thiol-coated gold surface. Immediately, 80 µL of potassium
buffer was added carefully. The CHT membrane preparation
was diluted 1:10 with potassium buffer and sonicated. Eight
microliter were added directly onto the SSM by submerging
the pipette into the buffer and the sensors were centrifuged for
30 min at 2,200 × g. The quality of the SSM was controlled
by determination of conductance σ and capacitance C. The
SURFE2R N1 device includes default functions to perform these
measurements. Sensors should have a conductance below 3 nS
and capacitance below 20 nF.
Electrophysiological Measurements
Prepared sensors were inserted into the faraday cage of the
SURFE2R N1 device and buffers applied via its automatic
perfusion system, allowing rapid buffer exchange in a continuous
liquid flow. The following buffer addition sequence was used
for all experiments: Sodium buffer was applied for 2 s with a
flow rate of 200 µl/s to establish a sodium gradient over the
membrane. Retaining the flowrate of 200 µl/s, choline buffer
was applied for 2 s and washed out again by sodium buffer (2 s).
During those 6 s the current response was recorded. At the end of
the recording the sensor was rinsed thoroughly with potassium
buffer. Only sensors generating current signals with amplitude
higher than 100 pA were used for experiments. Signals were used
for evaluation after the first activation, which showed greater
amplitude. A baseline subtraction was performed using sodium
free buffers.
Data Analysis
Raw data were exported as ASCII files, analysis was performed
using the scientific graphing and data analysis program IGOR
Pro 6 (WaveMetrics, Portland, USA). The evaluated peak
currents were determined using a peak detection algorithm.
For every average value, results from different sensors were
compared. The errors bars indicate the standard error of the
mean. Concentration response relationships for inhibition and
apparent affinity were obtained by perfusion of the sensors with
increasing compound concentrations. Inhibitors were added
to all three buffers. Data were normalized to the maximum
amplitude and described by fitting to a Hill function (Boyman
et al., 2009; Ottolia et al., 2009).
Radiometric Choline Uptake Assay
Uptake of [3H]Choline (American Radiochemicals; ART 0197;
1,000 Ci/vial; Specific Activity 60–90 Ci/mmol) was measured
in HEK cells expressing the high affinity choline transporter
(CHT), clone WT4. Cells were plated at 50,000 cells /well in
200 µL culture media on a PDL coated Cytostar-T 96 well
plate (Perkin Elmer) 24 h prior to assay. On the day of assay,
following two washes and a 30 min pre-incubation at 37◦C in 50
µL Na(−) free buffer (0.54 mM KCl, 1.3 mM CaCl2, 0.53 mM
MgCl2, 0.4 mM MgSO4, 0.37 mM KH2PO4, 240 mM Sucrose,
4.4 mM Tris-phosphate, 5.5 mM Glycine, 5.6 mM D-Glucose;
pH 6.5 with KOH), 25 µL 4X control or test compounds in
Na(−) buffer were added to the cells. Hundred and zero percent
controls were defined with 10 µM Staurosporine and DMSO
respectively. Final DMSO concentration was 0.25%. Following a
30 min incubation at 37◦C, 25 µL [3H]Choline diluted to 320
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nM (80 nM final concentration) was added in Na(+) buffer (0.54
mM KCl, 1.3 mM CaCl2, 0.53 mM MgCl2, 0.4 mM MgSO4,
0.37 mM KH2PO4, 138 mM NaCl, 0.28 mM Na2HPO4, 5.5 mM
Glycine, 5.6 mM D-Glucose; pH 6.5 with KOH). Plates were
sealed with TopSeals (Perkin Elmer) and incubated in darkness
for 3 h at room temperature before reading using a Wallac
Microbeta, 1 min/well. The assay window was typically 3-fold
signal to background ratio. A number of datasets fell outside of
assay acceptance criteria (defined as signal to background ratio
>3, individual assay plate Z prime (also known as z-factor) value
>0.3 and EC50 of a standard compound within the expected
range) and were therefore not included in the analysis.
Mass Spectrometric Choline Uptake Assay
All LC/MS analyses were performed on a Sciex 6,500 triple
quadrupole tandem mass spectrometer in positive electrospray
ionization (ESI) mode. Other instrumentation consisted of
Shimadzu LC-20AD pumps and an Apricot Design Dual Arm
Autosampler (ADDA). Liquid chromatography was performed
on a Waters Atlantis HILIC column (10 × 2.1 mm, 3µ). Mobile
phase A consisted of water with 0.1% formic acid and mobile
phase B consisted of water containing 0.1% formic acid and
acetronitrile containing 0.1% formic acid (50:50). The flow rate
was 0.6 mL/min and the gradient was as follows; hold at 100%
B for 5 s and switch to 100% A for 10 s and return to 100% B
for 5 s. Data were acquired with Analyst version 1.6. Quantitative
analysis was performed in the multiple reaction monitoring
(MRM) mode using MultiQuant software version 2.1. The MRM
transitions monitored were m/z 113/60 m/z for choline-D9
(deuterated choline chloride-(trimethyl-d9), Sigma Aldrich) and
108/60 m/z for the internal standard, choline-D4 (deuterated
choline chloride-1,1,2,2-D4, Sigma Aldrich).
Antibody Staining
A single cell clone of HEK293 overexpressing CHT (CHT-WT4)
cells was grown in 96 or 384 well format to 50% confluency.
Media was removed and cells were washed once with HBSS
(+/+). 1µg/mLAnti-FLAG antibody (F3165, Sigma) was diluted
in HBSS (+/+) and added to the cellular monolayer for 30 mins.
After incubation, cells were washed three times with HBSS (+/+)
followed by incubation with 1:5,000 AF488 labeled secondary
antibody (LifeTech) diluted in HBSS (+/+) for 30min. After
three washes, cells were fixed with 4% paraformaldehyde in HBSS
(+/+) for 15min. Nuclei were counterstained with the nuclear
dye Hoechst. All images were captured and analyzed on an
epifluorescent microsope or Cellomics platform.
RESULTS
Stable Cell Line Generation and
Characterization
Historically, animal-derived materials such as synaptosomes and
primary culture have been used to study CHT function. We
sought to move away from these approaches in accordance
with UK NC3R guidelines. We generated and characterized a
range of stable recombinant cell lines in both HEK-293 and
SH-SY5Y backgrounds as neuronal-like cell lines in order to
assess CHT transporter function for drug discovery. In the
HEK-293 background, stable pools with either wild-type (WT)
or mutant (LV-AA) CHT constructs were expanded and used
to generate genetically homogenous clonal lines using single
cell flow cytometry. Pools were used for initial radiometric
assay development which facilitated subsequent selection of
the CHT-WT4 line over other clones. This was done on the
basis of greater assay window for inhibition and activation
of [3H Choline] uptake (using 1 µM HC-3 and 10 µM STS
respectively; Supplementary Figure 1) and data reproducibility.
Interrogation of CHT-WT4 revealed overexpression of the
codon-optimized CHT transcript but not endogenous SLC5A7
transcript as measured by qPCR but no differential expression of
other choline transporters (SLC6A12/BGT1, SLC44A1-4/CLT1-
4) (Supplementary Figure 2A). Similarly, there is no differential
expression of other molecules required for acetylcholine
synthesis (CHAT), transport (SLC18A3/vAChT) or hydrolysis
(ACHE); nor in muscarinic and nicotinic acetylcholine receptor
subunits (Supplementary Figures 2B,C). Parallel experiments
were performed on the SH-SY5Y stable cell lines which
overexpressed the codon-optimized CHT-GFP fusion transcript
in addition to some basal SLC5A7 expression in parental
cells in addition to ACHE, SLC18A3, and CHAT expression
(Supplementary Figures 2D–F). These cell lines were the basis
for assessing a range of assays to identify and characterize
molecules that increased CHT-mediated transport (Table 1).
Assessment of Transporter Function Using
Membrane Potential has Utility as an
Orthogonal Assay Format
CHT is sodium (Na+) and chloride (Cl−) dependent and
requires a negative membrane potential; hence, alterations in
membrane potential can be used as a measure of CHT-mediated
transport. Indeed, Blakely and colleagues reported the discovery
of ML-352, a novel non-competitive inhibitor and STS as a
positive modulator of CHT using a membrane depolarized assay
(Ruggiero et al., 2012; Ennis et al., 2015). Building on these
observations, we evaluated the SURFE2RTM platform (Nanion
Technologies), as a solid supported membrane (SSM) based
electrophysiology platform to assess electrogenic transporter
activity (Bazzone et al., 2013; Barthmes et al., 2016). Membrane
fragments containing the protein of interest are immobilized
on a gold electrode several millimeters in diameter to facilitate
detection of transporter currents. Synchronous activation of
the transport proteins is triggered by rapid application of
a substrate-containing buffer. During electrogenic transporter
action, charge accumulates in the membrane fragments which
directly correlate with the measurable current on the gold
electrode and thus enables flexible, robust real timemeasurement
of transporter activity. Membrane preparations are essentially
“cell free” preparations minimizing trafficking impacts such
that any effect seen is likely to be a result of direct action
of compound or other treatment on the transporter. However,
it should be noted that the comparatively low proportion of
CHT proteins at the plasma membrane may be a limiting
factor for assays made using the SURFE2RTM. In the first
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TABLE 1 | Method comparison.
Type of readout Assay Pros Cons Notes
Direct measure of
transport function
[Choline] uptake into
synaptosomes
• Gold standard, decades of
literature precedence
• Radioactive
• Low throughput
• Uses ex-vivo preparations,
does not uphold UK NC3R
ideals
• Data not shown
[Choline] uptake detected by
scintillation proximity assay
(SPA)
• Recapitulates gold-standard
inhibitor data
• Potential for further assay
development (e.g., 384 well,
automation)
• Radioactive
• Less sensitive than gold
standard assay, compressed
assay window
• Low-to-medium throughput
• Requires adherent cells
• Data shown for HEK293 CHT-WT4;
comparable data sets not shown
for HEK293 CHT-LVAA and
SH-SY5Y CHT-GFP cell lines
D9-choline uptake detected by
LC/MS (liquid
chromatography/mass
spectrometry)
• Recapitulates gold-standard
inhibitor data
• Reasonable throughput
• 384 well format possible
• Increased sensitivity compared
to radiometric format
• Saturable—can measure
kinetics, mechanism etc
• High throughput options for
large compound collections
may be limiting
• Data generated for HEK293 CHT-
WT4 only
• Potential to be modified for
metabolic fate studies (see below)
and for in-vivo/ex-vivo approaches
(e.g., MALDI-Ach; Shariatgorji
et al., 2014)
Brominated choline detected by
X-ray fluorescence
• Potentially comparable to
D9-choline LC/MS approach
• Suitable ligand needs to be
identified
• Did not fully assess format
Electrogenic
measurement of transport
function
Nanion SURFE2R to detect
membrane potential changes
• Recapitulates gold-standard
data
• Analogous to validated
approach (Ennis et al., 2015)
• Low-to-medium throughput
• Requires large amounts of
membrane preparation
• Data shown for HEK293 CHT-WT4
Transporter localization FLAG-tagged live cell labeling • Potential for mechanistic
transporter assessment
• Low throughput
• Less sensitive than gold
standard assay
• Challenging to generate
IC/EC50
• See discussion
FAP (fluorogen activated
peptide) tagged assessment
• Potential for detailed
transporter mechanism
assessment
• Requires generation of
custom cell line (performed
under contract by Sharp
Edge Laboratories)
• Preliminary data suggests custom
cell line does not transport [choline]
despite apparent compound
effects on transporter localization
(data not shown)
Hemicholium-3 binding assay • Literature precedence
• Potential to generate
Bmaxdata
• Requires large amounts of
radioactivity
• Potentially confounding
observations given that
inhibitor (HC-3 and ML-352)
treatment increases cell
surface localization
• See discussion
Other in vitro assays Metabolic fate of transported
D9-labeled choline
• Non-radioactive • Low throughput • Potential for proof-of-concept
experiments to test key hypothesis
that increasing CHT function
impacts on ACh resynthesis and
release
• Preliminary experiments suggest
feasibility of approach (data not
shown)
In vitro acetylcholine
quantitation assay
• Non-radioactive • Low throughput
• Highly variable and not very
sensitive
• Gold-standard uses radiolabeled
choline which gets taken up
by presynaptic terminals and
presumably used to synthesize
acetylcholine
• Preliminary data suggests room for
improvement
(Continued)
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TABLE 1 | Continued
Type of readout Assay Pros Cons Notes
Chemical biology approaches • Literature describing tagged
choline mimetics informing
design of tools (fluorescent,
biotinylated and clickable
tools)
• Unclear how much tolerance
transporter has for chemical
substitution or other
substrates
• Low throughput
• Preliminary experiments failed to
recapitulate literature approaches
Slotboom transport dynamics
assay
• Detailed assessment to inform
on structure and transport rate
(Erkens et al., 2013)
• Low throughput and labor
intensive
• Ideally requires crystal
structure information
• Non-radioactive
• Did not assess
In-vivo impact of tool
compounds (ideally at
least 2 chemotypes) on
choline clearance, ACh
resynthesis and release
Ileum preparation • Could inform on probability of
parasympathetic side effect
• Proven utility for assessing
inhibitors
• Novel approach, requires
further method development
• Preliminary data using
overexpressing mouse model did
not see any effect with genotype or
compounds—but we did not
observe increased choline uptake
in synaptosomes from
overexpressing mice (data not
shown)
Amperometry in brains of
anaesthetized animals
• Previous literature suggests
feasibility of approach (Parikh
and Sarter, 2006)
• Labor intensive, would
require prior compound
triaging
• Preliminary experiments suggests
recapitulation of literature data (not
shown)
Acute slice culture • Potential for more throughput
(parallel assessment in slices)
• Assay development required
Behavioral assessment in
relevant animal model
• Potential for disease relevance
and/or phenotype relevance
• Labor intensive and low
throughput
• dSAT (sustained attention task in
presence of distractor) task likely to
be most informative (Parikh et al.,
2013); perform vs. AChEI
In vivo safety assessment Parasympathetic side effect
assessments
• Methods exist for assessment
e.g., cardiovascular telemetry,
urination, defecation
(metabolic cages),
gastrointestinal motility,
functional observational
battery
• Perform vs. AChEI
instance, we demonstrated that the Na+ and pH dependence
of CHT mediated choline transport could be recapitulated
using membrane preparations from CHT-WT4 (Figure 1A).
Furthermore, we were able to saturate the assay with an apparent
Ka of 25 µM (Figure 1B) and noted the measured signal
was stable over time (Supplementary Figure 3). We observed
inhibition of current with HC-3 (Figure 1C) and ML-352
(Figure 1D) with IC50 estimates of 20.4 and 70.1 nM respectively
(Table 2). However, we were not able to detect any effect of
staurosporine (STS) or MKC-231.
Radiometric Assessment of CHT Mediated
Transport Function was not Suitable for
Screening
SSM based approaches have utility as an orthogonal approach
but may be currently limited by throughput; additionally we
were also unable to observe positive effects of STS on CHT-
related currents (see Section Discussion). A preponderance
of literature precedent for measuring high affinity choline
uptake (HACU) utilizes a radiometric assay to measure
[3H]Choline transport in preparations. In order to measure
CHT-mediated transport activity, we established a radiometric
assay based on a measure of proximity-induced scintillation
in recombinant cell lines (Figure 2A) which had increased
throughput compared to traditional approaches. We observed
an increase in [3H]Choline uptake in CHT-WT4 cells compared
to the parental HEK293 background (Figure 2B) together with
a concentration-dependent increase in [3H]Choline uptake
(Supplementary Figure 4A). In addition, we recapitulated
literature observations of sodium dependency (Figure 2C),
consistent with known Na+ dependent choline co-transport
activity as well as recapitulating pH dependency observations
(Figure 2D) (Okuda et al., 2000). A number of parameters
were assessed in assay development including cell seeding
density, time of assay post-seeding, plate coating, buffer
composition, read time and choline concentration. We noted
that choline starvation and use of a sodium gradient and
manipulating pH (decreasing pH increases STS response)
improved assay window. We also observed the STS mediated
enhancement of [3H]Choline was stable over time and there
was reduced variability which led to the selection of a 3 h
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FIGURE 1 | Solid supported membrane based assays to evaluate CHT transport function. (A) Na+ and pH dependent effects on CHT. Normalized peak
current is increased with higher pH. Compare pH 8.2, blue, vs. pH 6.0, red (p = 0.0002, 1-way ANOVA). Absence of Na+ leads to a decrease in current. Compare
presence of Na+, blue, with absence of Na+, green (p = 0.0015, 1-way ANOVA). (N = 11). Error bars represent ± standard deviation. (B) Apparent choline affinity is
measured by application of solution containing differing choline concentrations as indicated. EC50[choline] 25 ± 6 µM (N = 10). Hill coefficient: 0.5. (C,D) Normalized
peak current was decreased by application of different concentrations of (C) HC-3: IC50 20.4 nM (N = 12) and (D) ML-352: IC50 70.1 nM (N = 13).
time point for screening purposes (Supplementary Figure 4B).
However, a complete saturation curve could not be generated
as the 3H-[choline] contained ethanol as a diluent which
was toxic to the cells at higher concentrations; a limitation
of this assay format. We proceeded to assess reported tools
in this assay which was capable of reading out on both
inhibitory and stimulatory activities (Table 2). Inhibition of
CHT mediated transport was seen with the classic inhibitor
hemicholinium-3 (HC-3) with an IC50 estimate of 116 nM
(Figure 2E) in addition to the recently described negative
allosteric modulator ML-352 with an IC50 estimate of 549 nM
(Figure 2F) which is in broad agreement with literature
observations (Okuda et al., 2000; Ennis et al., 2015). We
further recapitulated the reported stimulatory effect of
staurosporine (STS) on CHT-mediated transport (Ruggiero
et al., 2012) with an EC50 estimate of 1.7 µM in CHT-WT4
cells (Figure 2G) but no apparent effect in CHT-LVAA
pools (data not shown). We were unable to satisfactorily
demonstrate potentiation of CHT transport with STS in SH-
SY5Y cell backgrounds due to toxicity. We were also unable
to see any impact of positive allosteric modulator MKC-
231 (Takashina et al., 2008b) on CHT mediated transport
(Figure 2H).
We selected a set of 887 Pfizer compounds selected
via the Cresset field-based virtual screening technology,
(Cheeseright et al., 2007) using seed molecules CHT PAM
MKC-351/coluracetam (Takashina et al., 2008b) and CHT NAM
ML-352 (Ennis et al., 2015) (Supplementary Figure 4). This
library was initially screened in the CHT radiometric assay in
a 96 well format at 1 and 10 µM compound concentrations.
Actives identified in the 1 and 10 µM single point screens were
then assessed in a 10-point dose response format (Table 2).
Compounds 1, 2, and 3 were confirmed as positive allosteric
CHT modulators with EC50 estimates of 0.3, 0.4, and 4.5 µM
respectively. Compounds 4 and 5, with EC50 estimates of
1.5 and 0.7 µM respectively, were characterized as negative
allosteric modulators of CHT function. The Chemogenomic
Library (CGL) was also screened in the CHT radiometric assay
in a 96 well format at 10 and 1 µM concentrations. From this
screening campaign, a number of positive CHT modulator hits
(compounds 6-9, Table 2) were identified. The CHT radiometric
assay identified CHT modulators from both the field-based
virtual screening campaign and the Chemogenomic Library
(CGL) screen. However, as a consequence of the small assay
window, inter-assay variation was high and not all datasets fell
within the assay acceptance criteria as defined in the Materials
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and Methods section. This, coupled with our inability to
satisfactorily perform saturation analyses, prompted us to assess
alternative screening platforms.
Mass Spectrometry Assessment of
Transport Function Enabled Screening to
Identify Novel Positive Modulators
As highlighted in Section Radiometric assessment of CHT
mediated transport function was not suitable for screening, given
the challenges of our radiometric assay for high throughput
screening, alternative methods for measuring choline uptake
suitable for screening compound libraries were sought. We
elected to focus on measuring transport of a stably labeled
form of choline (deuterated choline chloride-(trimethyl-d9); D9-
choline) coupled with mass spectrometric based quantification
(Koc et al., 2002; Shariatgorji et al., 2014; Iwamoto et al., 2016).
Using this method, we observed a clear increase in D9-choline
uptake in HEK293 CHT-WT4 recombinant cells compared to
the parental background (Figure 3A). Critically, we were also
able to saturate transporter function using this method which
led us to determine a Km of 7.0 µM (Figure 3B), consistent
with literature reports (Okuda and Haga, 2000; Okuda et al.,
2000). Further validation of the mass spec assay using our
tool compounds revealed the capacity of the assay to report
on both inhibitory and potentiation activities. Pleasingly, we
observed a good agreement with obtained IC50 estimates for
HC-3 (5.6 nM) and ML-352 (41.9 nM); and EC50 estimates of
STS (507 nM) with those obtained in the radiometric assay and
in the published literature (Figures 3C–E and Table 2). Again,
we saw no apparent effect of MKC-231 (Figure 3F), consistent
with lack of activity in all other assay formats. We successfully
miniaturized the assay to a 384 well format with consistent z
prime >0.5 (Supplementary Figure 6). As a proof of concept
study, we screened the Chemogenomic Library (CGL) at 1 and
10 µM with DMSO as the negative control and 10 µM STS as
the positive control. A number of hits with either inhibitory or
stimulatory activities were identified, and these hits confirmed
with 10 point EC50 dose response follow-up. As highlighted in
Table 2, compounds 6-9, flagged as CHT PAMs in the single
point radiometric assays, were identified as positive modulators
in themass spectrometry assay. These four compounds, all kinase
inhibitors, were selected for further assessment in orthogonal
assay formats (Tables 1, 2, Section Live cell staining reveals effect
on transporter localization with compound treatment).
Live Cell Staining Reveals Effect on
Transporter Localization with Compound
Treatment
CHT function has been proposed to be tightly regulated
through localization with a minority of transporters present
on the presynaptic membrane (<10% of the total population;
Ferguson and Blakely, 2004; Ribeiro et al., 2006, 2007; Black and
Rylett, 2012). Thus, understanding compound effects on CHT
density and activation state in the synaptic membrane may aid
interpretation of the effects on cholinergic neurotransmission.
Conventional methods such as cell surface biotinylation present
challenges in terms of the requirement of large quantities of
cells and low throughput. The predicted topology of CHT
indicates 13 transmembrane domains, with an extracellular N-
terminus and intracellular C-terminal tail (Okuda et al., 2012).
Our CHT overexpression construct contains a FLAG tag on the
N-terminus which we sought to utilize with antibody detection
in non-permeabilized cells. However, we found that fixation of
cells with PFA or methanol gave rise to some permeabilization
and labeling of the internal CHT pool as indicated by
immunostaining for the V5 epitope tag at the intracellular C-
terminus (Supplementary Figure 7A). We therefore moved to
live cell immunolabeling to reduce artifacts. We used the CHT-
LVAA pool vs. CHT-WT4 cells to assess the effectiveness of this
approach in the first instance as this mutant protein has been
reported to exhibit increased cell surface localization through
a decrease in endocytosis (Ferguson et al., 2003; Ribeiro et al.,
2005, 2007; Ruggiero et al., 2012; Supplementary Figure 7B).We
proceeded to investigate the effect of compound treatment in
more detail. Cells were incubated with compounds at 1 or 10 µM
for 1 h before immunolabeling and visualization. Interestingly,
we observed an increase in cell surface localization with HC-
3, ML-352 and STS treatments whereas again, MKC-231 had
no apparent effect (Figure 4). We further tested compounds 6-
9, initially identified by screening in the radiometric and mass
spectrometry assays at 1 and 10 µM, and noted that compounds
8 and 9 both increased cell surface localization of CHT but
compounds 6 and 7 appeared to have no effects based on
qualitative observations (Figure 4).
DISCUSSION
In this manuscript, we report on two overlapping areas of
research: (1) seeking to develop novel approaches for identifying
and characterizing molecules that positively modulate high
affinity choline transport (ligand transport modulator), and (2)
the discovery of novel molecules that could be used as tools or
starting points for further medicinal chemistry efforts. It is worth
noting here that the methods we describe in this manuscript
have broader potential applications with respect to the field of
transporter biology.
Classical approaches to measuring HACU as a primary
function of CHT involve measuring the transport of radioactively
labeled choline in a relevant substrate. We were unable to
find a good immortalized source of human cholinergic neurons
suitable for large scale culture though there are some putatively
suitable murine lines (e.g., HT22) or stem cell derived cholinergic
models (Liu et al., 2013; Ho et al., 2016). We generated stable,
clonal lines in HEK-293 (a robust and well-understood line
with properties reminiscent of immature neurons) and SH-SY5Y
(neuroblastoma line which has been reported to differentiate
toward a cholinergic phenotype with retinoic acid) backgrounds.
These lines were characterized with respect to cholinergic
expression and function; we believe they serve as useful tools
for primary screening and other throughput approaches but
given the known caveats with overexpressing cell lines, we would
advocate further corroboration in a more “native” context.
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FIGURE 2 | Radiometric assay to evaluate CHT transport function. (A) Schematic showing principle of the radiometric assay format. A monolayer of CHT
expressing cells (green outline) are grown on plates with scintillant embedded in the base. Uptake of [3H] Choline (red) by cells brings the radioligand in proximity to
the scintillant giving rise to a signal that can be quantified. (B) Specific [3H] Choline uptake (plotted as cpm, counts per minute) observed in recombinant HEK293 cell
line overexpressing wild-type CHT (Clone 4, CHT-WT4, red) compared to the parental HEK293 background (blue) (N = 8–24; p < 0.0001, unpaired t-test). Bars
represent ± SD. (C) [3H] Choline uptake (plotted as cpm, counts per minute) is measured in the presence (red) or absence (blue) of sodium (Na) in the CHT-WT4 cell
line. A clear increase in choline uptake is observed in the presence of sodium (p < 0.0001, unpaired t-test, N = 18). Bars represent ± SD. (D) [3H] Choline uptake
(plotted as cpm, counts per minute) is measured at pH 5.5 (blue), 7.8 (red) and 9.5 (green). Uptake increases with increase in pH (Multiple comparisons performed
with 1-way ANOVA. pH 5.5 vs. pH 7.8 p = 0.0009; pH 5.5 vs. pH 9.5 p < 0.0001; pH 7.8 vs. pH 9.5 p = 0.019. N = 2). Bars represent ± SD. (E–H) 10-point dose
response curves to generate IC50 or EC50 estimates performed for HC3, IC50 116 nM (E), ML-352, IC50 549 nM (F), STS, EC50 1.7 µM (G), MKC231 (no apparent
effect) (H); (N = 8). Bars represent ± SD for each data point. Cpm, Counts per minute; refers to uptake of [3H] Choline.
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FIGURE 3 | Mass spectrometric assay to evaluate CHT transport function. (A) Specific D9-Choline uptake observed in recombinant HEK293 cell line
overexpressing wild-type CHT (Clone 4, CHT-WT4, red) compared to the parental HEK293 background (blue) (p < 0.0001, unpaired t-test. N = 3). Bars represent ±
SD. (B) Saturation of D9-Choline uptake in the presence of increasing concentration of D9-Choline (N = 2). Bars represent ±SD. (C–F) 10-point dose response
curves to generate IC50 or EC50 estimates performed for HC3, IC50 5.6 nM (C), ML-352, IC50 41.9 nM (D), STS, EC50 507 nM (E), MKC231, no apparent effect (F)
(N = 3). Bars represent ±SD for each data point.
Radiometric choline uptake, a direct assessment of the
transport function and detected by scintillation proximity assay
is a method we have previously used successfully [52, 53].
Assay development enabled us to refine parameters to increase
assay window including the use of sodium free buffer prior
to substrate and compound exposure to enhance the gradient
and pH manipulation. Two sets of compounds were screened
in the radiometric choline uptake assay. The first set was
selected using the field-based approach from Cresset (Section
Field Based Approach to Identifying Novel CHT Modulators,
Supplementary Figure 5). If, as is the case for the choline
receptor, structural information describing key ligand/protein
interactions between a bound active ligand and a protein of
interest is not available to act as a start point for virtual screening,
an alternative approach is to use a ligand-based method. The
Cresset approach computationally describes an active ligand as
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FIGURE 4 | Effect of compounds on CHT localization. Representative images showing effect of compounds on cell surface expression of CHT measured by
immunocytochemistry of the N-terminal FLAG tag (green) in live CHT-WT4 cells. Nuclei are counterstained with DAPI (blue). Vehicle represents 0.1% DMSO and
indicated compounds were used at a concentration of 10 µM. Images were captured at 40x magnification.
a 3D electrostatic and shape-based “field” to give a “protein’s
eye view” of how the compound interacts with the target. This
“field” is then utilized as a template to virtually screen compounds
collections in order to identify additional compounds with a
similar field and therefore biological activity (Cheeseright et al.,
2007). As discussed in Sections Chemogenomic Compound
library and Radiometric assessment of CHT mediated transport
function was not suitable for screening, 500 compounds based
on the CHT PAM modulator MKC-351/coluracetam (Takashina
et al., 2008b) and 500 compounds based on the CHT NAM
modulatorML-352 (Ennis et al., 2015) were selected for screening
from the Pfizer screening collection, based on their field scores.
We identified a number of positive and negative CHTmodulators
in our experiments (Table 2). Positive allosteric modulators 1-
3 were identified from the CHT PAM modulator MKC-351 and
negative allosteric modulators 4-5 were identified from the CHT
NAM modulator ML-352. Compounds 1-5 illustrate the value
of the field-based approach, with a more varied range of active
chemotypes identified than those that would be generated from
a simple substructure or 2D similarity search. It is important to
note that the original observations for the CHT PAM modulator
MKC-231 were made in the AF64A-treated rat hippocampal
synaptosomes with no impact of MKC-231 treatment on HACU
or HC-3 binding with vehicle treatment (Takashina et al.,
2008a,b). Consistently, we did not observe any impact of MKC-
231 treatment in any of our approaches which were performed in
the absence of AF64A treatment.
The Pfizer Chemogenomic Library (CGL) comprises
approximately 2,753 historical compounds covering 1,043
distinct mechanisms (thus testing each mechanism multiple
times) and was initially designed to support phenotypic
screening assays to help delineate which mechanisms may be
playing a role in the observed end point. Pleasingly, we identified
compounds with either inhibitory or stimulatory activities. The
initial stimulatory compound hits were further confirmed in 10
point dose response curves. Compounds 6-9 are examples of
kinase inhibitor actives from the Pfizer Chemogenomic Library
(CGL) screen highlighted in Table 2. Literature reports show
that CHT activity at the plasma membrane and subcellular
trafficking/internalization via endosomal compartments is
tightly controlled at least in part by post-translation mechanisms
(PTMs) with canonical consensus sequencemotifs in the primary
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 February 2017 | Volume 10 | Article 40
Choudhary et al. Increasing CHT Mediated Transport
amino acid sequence for phosphorylation and ubiquitylation;
motifs also exist for dimerization and clathrin-mediated
endocytosis (reviewed in Ferguson and Blakely, 2004; Black
and Rylett, 2012). Our observations raised the intriguing
possibility that these compounds may be exerting effects
through modifying CHT PTMs and its localization accordingly.
Compounds 6-9 were selected for further characterization
using the live cell antibody labeling to assess their impact on
CHT cell surface localization. Of the four compounds, two
were found to have no apparent effect on CHT localization on
the cell surface (compounds 6 and 7), whereas compounds 8
and 9 each elicited a distinct increase in apparent cell surface
localization. Interestingly, STS treatment also increased cell
surface localization. Additional analysis is required to determine
the specific kinase targets/pathways that may be responsible for
modulating the phosphorylation state of the CHT transporter
and increasing its retention at the cell surface.
In addition to STS treatment, our observations suggest
that treatment with inhibitors HC-3 or ML-352 also increase
transporter density on the cell surface which in turn invites
speculation about conformational changes that block CHT
internalization. We therefore suggest caution with respect
to interpretation of data from HC-3 binding assays as an
indication of active CHT present on the cell surface. Better
understanding of CHT conformation dynamics and structural
changes corresponding to activity would be invaluable using
approaches such as single-molecule FRET (Erkens et al., 2013).
Interestingly, preliminary data (not shown) generated under
contract by Sharp Edge Laboratories withN-terminalmodulation
of a CHT construct with a fluorogen activated peptide tag (Snyder
et al., 2015; Naganbabu et al., 2016; Plamont et al., 2016) appears
to have no effect on trafficking of CHT but potentially interferes
with [choline] transport.
Blakely and colleagues report the use of membrane potential
changes as a basis for identifying novel compounds to modulate
CHT given its electrogenic properties (Ruggiero et al., 2012;
Ennis et al., 2015). Data generated with tool compounds in
collaboration with Nanion Technologies on the SURFE2RTM
platform using membrane preparations enabled us to generate
direct, sensitive and functional measurements that correlated
well with those reported in literature (Table 2). This approach
is currently limited in terms of throughput but could be
advantageous for orthogonal validation or for deeper study
into mechanisms of action. An additional challenge in studying
CHT by this method is the relatively low proportion of active
transporter on the plasma membrane which may have been
addressed to some extent in the literature by using a preparation
from an LV-AA mutant form with higher transporter density
(Ruggiero et al., 2012; Ennis et al., 2015). It would additionally
be interesting to evaluate whether membrane fractions (e.g.,
plasma membrane vs. vesicles or endocytic machinery) would
impact on assay window. Lack of activity of STS on the
SURFE2RTM platform (Table 2) is further consistent with the
hypothesis that STS and STS-like compounds exert their
effect through an indirect kinase mechanism that in turn
modulates the phosphorylation state of the transporter and
increases its retention at the cell surface, as are published
data suggesting STS has modulatory effect in striatal but not
hippocampal synaptosomes (Ruggiero et al., 2012). Indeed,
further biological and pharmacological interrogations around
kinase inhibition and phosphorylation motifs and subsequent
impact on subcellular localization and trafficking kinetics would
be an interesting avenue to explore. Additional studies into the
underlying mechanisms of these novel compounds described
here include more detailed pharmacology experiments including
Km and Vmax determination and relative efficacy of distinct
mechanisms with respect to the fate of the transported choline
in addition to impact on synaptic vesicle based activities. It is
not currently clear whether there is sufficient transporter present
at the cell membrane to provide efficacy through direct positive
modulation.
The challenges (lack of saturation, requirement for high
[3H]Choline concentrations and small assay window) associated
with screening in the radiometric assay led us to seek alternative
approaches. Mass spectrometry has previously been reported
as a rapid, sensitive and directly quantitative approach with
respect to AChEI (Shariatgorji et al., 2014). In our hands,
mass spectrometry appeared advantageous with respect
to bidirectional readout, high sensitivity, reproducibility,
quantitative output, and compatible with throughput
optimisation (e.g., miniaturization, automation). Furthermore,
it appears amenable to more detailed kinetic, mechanistic and
quantitative studies. We are intrigued by the additional potential
to elucidate the fate of transported D9-choline through multiple
metabolic routes including detection of released D9-ACh into the
extracellular milieu; and associated possibilities for biomarker
development. We are similarly captivated by the potential of
X-ray fluorescence (Olabisi et al., 2016) with high throughput
label-free direct activity-based measurements in normal culture
conditions to identify compound effects on CHT overexpressing
cells. However, we do not know howmuch tolerance CHT has for
chemical modulation of specific groups and impact on substrate
function, for example in order to label a choline mimetic (i.e.,
bromination of the N-methyl group) that can be detected by
X-ray fluorescence.
Taken together, we outline a set of approaches suitable for
screening to identify and characterize novel small molecules
modulating transport function of CHT and selected other solute
carriers. Furthermore, we report the discovery of potential
positive ligand transport modulators for CHT which warrant
further investigation and validation as possible tools and/or
seeds for further medicinal chemistry efforts. We hope this
report will prime efforts toward testing the hypothesis that
positive modulation of CHT transport function is a relevant
therapeutic mechanism in an appropriate cholinergic deficit
model to determine level of restoration of function vs. positive
controls such as acetylcholinesterase inhibitors.
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Supplementary Figure 1 | [3H] Choline uptake in the presence of 0.25%
DMSO (Vehicle, blue), 1 µM HC-3 (red) and 10 µM STS (green) was
monitored in untransformed SK-N-FI and SH-SY5Y cell lines alongside
two clonal cell lines in the HEK293 background, CHT-WT4 and CHT-WT5,
and the pool from which clones were created, CHT-WT Pool. The inhibition
by HC-3 and activation by STS in the CHT-WT4, CHT-WT5 and CHT-WT Pool cell
lines was significant (Vehicle vs. HC3 and Vehicle vs. STS, p < 0.05 1-way
ANOVA. N = 4). CHT-WT4 exhibited the largest % inhibition by HC-3 (∼80%)
compared to CHT-WT5 (∼61%) and CHT-WT Pool (∼69%). The fold-activation by
STS was lower in CHT-WT4 compared to others suggesting that the uptake
window was not saturated. No effect of HC-3 or STS was seen in SK-N-FI and
SH-SY5Y lines.
Supplementary Figure 2 | Quantitative PCR used to measure expression of
indicated genes in recombinant CHT cell lines (red) in HEK293 (A–C) or
SH-SY5Y (D–F) backgrounds compared to the appropriate parental cell line
(blue). RPL19A is used as the housekeeping gene. A significant difference in CHT
(SLC5A7) expression was observed between the recombinant and parental lines
(p < 0.05, unpaired t-test, N = 3). Expression of no other gene was significantly
altered. Individual data points, together with their mean, are shown.
Supplementary Figure 3 | Membranes from CHT-WT4 were treated with
100 µM Choline at pH 8.2. The current amplitude signal measured on the
SURFE2R platform was observed to be stable over time with no significant
differences between any condition (1-way ANOVA, N = 4). Bars represent ± SD
for each data point.
Supplementary Figure 4 | (A) Measurement of [3H] Choline uptake in the
presence of increasing concentration of [3H] Choline (N = 2). (B) 10-point dose
response curves for STS generated at different time-points post addition of [3H]
Choline. (N = 2). Bars represent ± SD for each data point. Cpm, Counts per
minute; refers to uptake of [3H] Choline.
Supplementary Figure 5 | Selected images from Blaze results with
purported CHT modulator seed molecules (PAM MKC-351 and NAM
ML-352) (green) shown on the left and output molecules 1-5 shown on the
right (gray). Fields are shown with positive (red), negative (cyan), van der Waals
(yellow), and hydrophobic (orange) regions.
Supplementary Figure 6 | Table summarizing Z’ for screening with [D9]
Choline uptake. ZPE (zero percent effect) represents vehicle (0.1% DMSO) and
HPE (hundred percent effect) was generated with 10 µM Staurosporine.
Supplementary Figure 7 | (A) Representative images showing artifacts induced
by fixation of cells with 4% PFA for 15 min. Immunocytochemistry was performed
on HEK293-CHT cells expressing a CHT construct that is tagged with the FLAG
tag at the N-terminus and a V5 epitope at the C-terminal which projects
intracellularly. Immunocytochemistry in fixed cells under non-permeabilized
conditions results in detection of the intracellular V5 epitope (green) indicating
permeabilization introduced by the process of fixing alone. Nuclei are
counterstained with DAPI (blue). Images are captured at 10x magnification. (B)
Quantification of cell surface expressed CHT by the Cellomics software in
recombinant HEK293 cell lines stably expressing LV-AA (blue) or WT (red) CHT.
Increase in cell surface CHT is seen in the LV-AA condition (p < 0.0001, unpaired
t-test. N = 12). Bars represent ± SD.
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